Fennec Pharmaceuticals Inc. (FENC) stock
FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3088% above fair value
$13.58+0.82 (+6.43%)
Close on Nov 17, 2026Market cap $476.21MP/E –Yield –
Fennec Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Fennec Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$2.04M. For fiscal 2025 it was -$12.47M, down 146.2% from the year before. The highest annual figure on record is $26.98M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.47M | -146.2% |
| FY2024 | Dec 31, 2024 | $26.98M | – |
| FY2023 | Dec 31, 2023 | -$17.14M | – |
| FY2022 | Dec 31, 2022 | -$18.06M | – |
| FY2021 | Dec 31, 2021 | -$14.22M | – |
| FY2020 | Dec 31, 2020 | -$15.60M | – |
| FY2019 | Dec 31, 2019 | -$9.06M | – |
| FY2018 | Dec 31, 2018 | -$7.83M | – |
| FY2017 | Dec 31, 2017 | -$3.64M | – |
| FY2016 | Dec 31, 2016 | -$2.12M | – |
| FY2015 | Dec 31, 2015 | -$1.86M | – |
| FY2014 | Dec 31, 2014 | -$1.70M | – |
| FY2013 | Dec 31, 2013 | -$2.21M | – |
| FY2012 | Dec 31, 2012 | -$2.99M | – |
| FY2011 | Dec 31, 2011 | -$3.23M | – |
| FY2010 | Dec 31, 2010 | -$1.93M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $50.00K | – |
| Q1 FY2026 | Mar 31, 2026 | $2.38M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.96M | – |
| Q3 FY2025 | Sep 30, 2025 | $1.49M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.69M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.32M | -111.1% |
| Q4 FY2024 | Dec 31, 2024 | -$1.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.21M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.39M | – |
| Q1 FY2024 | Mar 31, 2024 | $39.05M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.86M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.76M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.95M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.58M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.80M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.01M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.39M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.86M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.25M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.96M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.43M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.59M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.28M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.45M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.12M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.75M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.59M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.24M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.76M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.48M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.93M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.60M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.57M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.73M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.32M | – |
| Q3 FY2017 | Sep 30, 2017 | -$958.00K | – |
| Q2 FY2017 | Jun 30, 2017 | -$688.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$675.00K | – |
| Q4 FY2016 | Dec 31, 2016 | -$611.00K | – |
| Q3 FY2016 | Sep 30, 2016 | -$544.00K | – |
See a number that looks wrong?